Fernando Lara-Medina
Overview
Explore the profile of Fernando Lara-Medina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferrigno Guajardo A, Vaca-Cartagena B, Mayer E, Bousrih C, Oluchi O, Saura C, et al.
J Natl Cancer Inst
. 2023 Dec;
116(2):239-248.
PMID: 38059798
Introduction: The addition of taxanes to anthracycline-based chemotherapy is considered standard of care in the treatment of breast cancer. However, there are insufficient data regarding the safety of taxanes during...
2.
Munoz-Montano W, Cabrera-Galeana P, De la Garza-Ramos C, Azim Jr H, Tabares A, Perez V, et al.
Breast Cancer Res Treat
. 2021 Jun;
188(2):489-500.
PMID: 34132938
Purpose: Pregnancy-associated breast cancer (PABC) poses a clinical challenge and its prognosis remains controversial. During the pregnancy and postpartum periods, the breast undergoes biological events that may uniquely influence disease...
3.
Munoz-Montano W, Cabrera-Galeana P, Alvarado-Miranda A, Villarreal-Garza C, Mohar A, Olvera A, et al.
Clin Breast Cancer
. 2020 Apr;
20(4):307-316.e1.
PMID: 32305297
Purpose: Neutrophils are among the key cellular players in the inflammatory milieu produced in patients with breast cancer (BC), and strong evidence exists in terms of the prognostic value of...
4.
Cabrera-Galeana P, Soto-Perez-de-Celis E, Reynoso-Noveron N, Villarreal-Garza C, Lara-Medina F, Alvarado-Miranda A, et al.
Oncologist
. 2020 Apr;
25(12):1023-1031.
PMID: 32275801
Background: Older patients with breast cancer treated in high-income countries often present with early-stage disease, leading to a lack of information on the use of neoadjuvant chemotherapy in this population....
5.
de la Rosa Oliva F, Meneses Garcia A, Ruiz Calzada H, Astudillo de la Vega H, Bargallo Rocha E, Lara-Medina F, et al.
Nutr Hosp
. 2019 Jun;
36(4):769-776.
PMID: 31192682
Background: antineoplastic treatment for locally advanced breast cancer (LABC) includes neodjuvant chemotherapy (NeoCT). However, side effects occur frequently, affecting the functional capacity and quality of life of patients as a...
6.
Flores-Diaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus J, et al.
Breast Cancer Res Treat
. 2019 Apr;
176(1):243-249.
PMID: 30997623
Purpose: The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in...
7.
Mohar-Betancourt A, Alvarado-Miranda A, Torres-Dominguez J, Cabrera P, Lara-Medina F, Villarreal-Gomez Y, et al.
Salud Publica Mex
. 2018 May;
60(2):141-150.
PMID: 29738653
Objective: To evaluate the prognostic factors (clinicalpathological characteristics and treatments) in patients with breast cancer and metastasis to central nervous system (CNS) as the first site of the disease. Material...
8.
Cabrera-Galeana P, Soto-Perez-de-Celis E, Reynoso-Noveron N, Villarreal-Garza C, Arce-Salinas C, Matus-Santos J, et al.
J Geriatr Oncol
. 2018 Apr;
9(6):620-625.
PMID: 29691196
Introduction: Although the epidemiology of breast cancer in older women has been widely described before, little is known about the clinical characteristics and prognosis of older patients living in developing...
9.
Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy
Cabrera-Galeana P, Munoz-Montano W, Lara-Medina F, Alvarado-Miranda A, Perez-Sanchez V, Villarreal-Garza C, et al.
Oncologist
. 2018 Mar;
23(6):670-678.
PMID: 29490940
Background: Several breast cancer (BC) trials have adopted pathological complete response (pCR) as a surrogate marker of long-term treatment efficacy. In patients with luminal subtype, pCR seems less important for...
10.
Reynoso-Noveron N, Villarreal-Garza C, Soto-Perez-de-Celis E, Arce-Salinas C, Matus-Santos J, Ramirez-Ugalde M, et al.
J Glob Oncol
. 2017 Dec;
3(6):757-764.
PMID: 29244990
Purpose One half of the Mexican population lacks comprehensive health care coverage. In 2003, a reform to the General Health Law was approved that led to the creation of the...